A Phase 3, Multi-Center, Open-Label, Randomized, Clinical Trial Evaluating the Efficacy and Safety of Technosphere Insulin Inhalation Powder in Combination With Lantus Versus Humalog in Combination With Lantus in Subjects With Type 1 Diabetes Mellitus Over a 16-Week Treatment Period

Trial Profile

A Phase 3, Multi-Center, Open-Label, Randomized, Clinical Trial Evaluating the Efficacy and Safety of Technosphere Insulin Inhalation Powder in Combination With Lantus Versus Humalog in Combination With Lantus in Subjects With Type 1 Diabetes Mellitus Over a 16-Week Treatment Period

Discontinued
Phase of Trial: Phase III

Latest Information Update: 21 Oct 2014

At a glance

  • Drugs Insulin (Primary) ; Insulin glargine; Insulin lispro
  • Indications Type 1 diabetes mellitus
  • Focus Registrational; Therapeutic Use
  • Sponsors MannKind Corporation
  • Most Recent Events

    • 15 Oct 2014 Status changed from completed to discontinued, as reported by the ClinicalTrials.gov record.
    • 28 Jun 2011 Results presented at the 71st Annual Scientific Sessions of the American Diabetes Association.
    • 28 Jun 2011 Treatment satisfaction outcomes presented at the 71st Annual Scientific Sessions of the American Diabetes Association.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top